Aug 09, 2023 / 08:30PM GMT
Sumant Kulkarni - Canaccord Genuity - Analyst
Good afternoon, everyone. I'm Sumant Kulkarni, a senior biotechnology analyst with Canaccord Genuity. And it's my pleasure to have Stoke Therapeutics here today at a very interesting time for the company. We are awaiting more data from the trials that you're running in the first quarter of 2024, and the program has generated has the investor debate. And you are doing pioneering things in the space that you're targeting. So we're very happy to have you here.
For Stoke, we have CEO, Ed Kaye, and CMO, Barry Ticho. So we'll go into it -- I guess I'll ask you to give a short intro of what Stoke is all about, your platform technology and the indication you're going after first, and then we'll go straight into Q&A. And if anyone has any questions, please feel free to raise your hand. We'll get a mic over to you. So with that, over to you, Ed.
Ed Kaye - Stoke Therapeutics, Inc. - CEO & Director
Sure. So Stoke Therapeutics is a RNA company that's really focused on splicing to upregulate protein expression.
Stoke Therapeutics Inc at Canaccord Genuity Growth Conference Transcript
Aug 10, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers